Case 1:22-cv-00252-MSG Document 134-3 Filed 10/03/23 Page 1 of 4 PageID #: 1840
`Case 1:22-cv-00252-MSG Document 134-3 Filed 10/03/23 Page 1 of 4 PagelD #: 1840
`
`EXHIBIT J
`EXHIBIT J
`
`

`

`Case 1:22-cv-00252-MSG Document 134-3 Filed 10/03/23 Page 2 of 4 PageID #: 1841
`
`From:
`To:
`Cc:
`Subject:
`Date:
`
`Afinogenova, Alina
`Sheh, Anthony; shaelyndawson@mofo.com; *jshaw@shawkeller.com; Karen Keller; Nate Hoeschen; Genevant Team; Arbutus_MoFo
`Carson, Patricia A.; Wacker, Jeanna; McLennan, Mark C.; Appler, Hunter; Tabrizi, Maryam; Blumenfeld, Jack; Egan, Brian P.; Murray, Travis; #KEModernaSpikevaxService
`RE: Arbutus v. Moderna, 1-22-cv 00252 - Moderna"s Search Terms - Highly Confidential - Outside Counsel"s Eyes Only
`Friday, September 22, 2023 3:47:41 PM
`
`HIGHLY CONFIDENTIAL – OUTSIDE COUNSEL’S EYES ONLY
` 
`Tony,
` 
`Below are the revised hit counts for Plaintiffs’ proposed revisions, which are extremely overbroad, unduly burdensome, and not sufficiently targeted to relevant material, totaling
`421,622 documents including family members. Although we do not agree that any of Plaintiffs’ revisions are justified or proportional, in the interest of compromise and moving
`things along quickly, we’ve agreed to many of the searches, as indicated below. Based on the extreme number of documents that Plaintiffs are seeking, Moderna will be running
`email thread de-duplication. The remaining searches are extremely overbroad and will not be run unless Plaintiffs propose significant narrowing to relevant subject matter and/or
`time periods. We’ve included abbreviated objections below and are willing to discuss them with Plaintiffs, if needed.
` 
`Please get back to us no later than Tuesday COB with any final proposed revisions to the remaining searches.
` 
`Regards,
`Alina
` 
` 
` 
`
`#
`
`I-01
`
`I-01.1
`
`I-02
`
`I-03
`
`I-04
`I-05
`I-06
`I-07
`I-08
`
`I-09
`I-10
`
`I-11
`
`I-12
`
`I-13
`
`I-14
`
`I-15
`
`I-16
`I-17
`
`I-18
`
`I-19
`
`Search Term
`
`(LNP OR (lipid W/1 nanoparticle*)) W/7 (mRNA OR
`messenger RNA)
`
`Start
`Date
`28-Feb-2012
`
`End
`Date
`28-Feb-2022
`
`8
`
`Custodians
`
`Hits +
`Family
`118,208
`
`((LNP OR (lipid W/1 nanoparticle*)) W/7 (mRNA OR
`messenger RNA)) AND (ratio* OR (lipid W/2 molar) OR (lipid
`W/2 content*) OR (lipid W/2 concentration*) OR (lipid W/2
`conc) OR "##mol \u0025" OR "##mol\u0025" OR mRNA-
`1273* OR (mRNA W/1 1273*) OR Spikevax* OR
`Elasomeran* OR licens* OR agreement OR sublicense OR
`sublicens* OR sub-licens*)
`(LNP OR (lipid W/1 nanoparticle*)) W/7 siRNA
`
`(SM-102 OR SM102 OR SM-000102) W/15 (mRNA-1273 OR
`Spikevax* OR Elasomeran*)
`(SM-102 OR SM102 OR SM-000102) W/10 PEG*
`(SM-102 OR SM102 OR SM-000102) W/10 cholesterol
`(SM-102 OR SM102 OR SM-000102) W/10 DSPC
`(SM-102 OR SM102 OR SM-000102) W/15 "##mol\u0025"
`(SM-102 OR SM102 OR SM-000102) W/15 (molar ratio OR
`lipid ratio OR ratio of lipids)
`(SM-102 OR SM102 OR SM-000102) W/15 (lipid W/2 ratio)
`(SM-102 OR SM102 OR SM-000102) W/10 (stability OR
`(tissue W/2 clearance) OR (mRNA W/2 delivery))
`(SM-102 OR SM102 OR SM-000102) W/7 (mRNA OR
`messenger RNA)
`
`(SM-102 OR SM102 OR SM-000102) W/7 (LNP OR (lipid
`W/1 nanoparticle*))
`(SM-102 OR SM102 OR SM-000102) W/10 (MC3 OR DLin-
`MC3-DMA)
`(MC3 OR DLin-MC3-DMA OR ALC-0159) W/10 ((plasmid
`W/2 DNA) OR siRNA OR mRNA OR SM-102 OR SM102 OR
`SM-000102)
`
`(entrap* OR encapsulat*) W/3 (assay* OR test* OR stud*
`OR efficienc* OR rate OR percent*)
`fully W/3 encapsulat*
`(Inex OR Protiva OR Genevant OR Tekmira OR Arbutus)
`W/10 (lipid OR LNP OR mRNA OR siRNA OR ratio* OR
`patent* OR (intellectual W/1 propert*) OR IP OR licens* OR
`agreement OR sublicense* OR sub-licens*)
`(Acuitas OR AlCana OR Alnylam) W/5 (lipid OR LNP OR
`mRNA OR siRNA OR ratio* OR patent* OR (intellectual W/1
`propert*) OR IP OR licens* OR agreement OR sublicens* OR
`sub-licens*)
`((cation* OR ioniz*) W/2 lipid) W/10 (mRNA OR siRNA)
`
`28-Feb-2012
`
`28-Feb-2022
`
`HB
`
`36,444
`
`28-Feb-2012
`
`28-Feb-2022
`
`8 + AT
`
`10,136
`
`28-Feb-2016
`
`28-Feb-2022
`
`8 + AT
`
`28-Feb-2016
`28-Feb-2016
`28-Feb-2016
`28-Feb-2016
`28-Feb-2016
`
`28-Feb-2022
`28-Feb-2022
`28-Feb-2022
`28-Feb-2022
`28-Feb-2022
`
`8 + AT
`8 + AT
`8 + AT
`8 + AT + HB
`8 + AT + HB
`
`28-Feb-2016
`28-Feb-2016
`
`28-Feb-2022
`28-Feb-2022
`
`8 + AT + HB
`8 + AT
`
`28-Feb-2016
`
`28-Feb-2022
`
`8 + AT + HB
`
`28-Feb-2016
`
`28-Feb-2022
`
`8 + AT
`
`28-Feb-2016
`
`28-Feb-2022
`
`8 + AT
`
`28-Feb-2016
`
`28-Feb-2022
`
`8 + AT + HB
`
`28-Feb-2016
`
`28-Feb-2022
`
`8 + AT + HB
`
`28-Feb-2016
`28-Feb-2016
`
`28-Feb-2022
`28-Feb-2022
`
`8 + AT + HB
`8 + AT + HB
`
`12,899
`
`34,634
`23,293
`28,360
`7,605
`1,471
`
`3,409
`11,995
`
`45,613
`
`33,962
`
`21,796
`
`49,186
`
`33,472
`
`616
`3,840
`
`28-Feb-2016
`
`28-Feb-2022
`
`8 + AT + HB
`
`7,149
`
`28-Feb-2016
`
`28-Feb-2022
`
`8 + AT + HB
`
`22,089
`
`Objections
`
`Overbroad including w/r/t
`time periods; if Plaintiffs want
`longer time periods they
`should reduce the proximity
`connector or add further
`limiting terms.
`Overbroad; not limited to
`accused product.
`
`Overbroad; if Plaintiffs want
`longer time periods they
`should reduce the proximity
`connector.
`Accept
`
`Accept
`Accept
`Accept
`Accept
`Accept
`
`Accept
`Accept
`
`Overbroad; not limited to
`aspects of accused product
`relevant to asserted claims.
`Accept
`
`Accept
`
`Overbroad; encompasses
`comparisons to unclaimed
`lipids and there are 10 other
`SM-102 strings.
`Accept
`
`Accept
`Accept
`
`Overbroad, especially
`considering attenuated
`relevance.
`
`Overbroad; Plaintiffs should
`reduce proximity connector if
`they want additional
`custodians.
`
`

`

`Case 1:22-cv-00252-MSG Document 134-3 Filed 10/03/23 Page 3 of 4 PageID #: 1842
`
`Overbroad for reasons
`previously explained;
`disproportionate considering
`
`that Plaintiffs have offered
`
`minimal relevance bases.
`
`
`
`
`
`
`
`(Emergency Use Authorization OR EUA OR ((BLA OR 28-Feb-2016|28-Feb-2022 97,724 Overbroad;if it is intended to
`
`Case 1:22-cv-00252-MSG Document 134-3 Filed 10/03/23 Page 3 of 4 PagelD #: 1842
`
`
`
`
`
`Biologics License) W/5 125752*) OR ((IND OR
`capture relevant aspects of
`
`Investigational New Drug) W/5 19745*)) AND ((lipid W/2
`regulatory filings for the
`
`
`molar) OR(lipid W/2 content*) OR(lipid W/2
`accused product, no basis to
`concentration*) OR(lipid W/2 conc.) OR (intellectual W/1
`go back to 2016.
`
`
`propert*) OR target* OR chang* OR approv* ORlipid* OR
`
`
`LNP* OR composit* OR formulat* OR PEG* ORratio* OR
`
`
`""##mol \u0025"" OR ""##mol\u0025"" OR batch* OR
`
`
`encapsulat* OR patent*)
`
`
`
`
`
`
`Biologics License) W/5 125752*) OR ((IND OR
`“mg/ml” not sufficiently
`
`
`Investigational New Drug) W/5 19745*)) AND(IP ORlicens*
`limited; many otherlicensing
`OR agreement OR sublicense* OR sub-licens* ORinfring*
`strings already capturing
`
`
`relevantESI.
`
`
`OR mg/mL)
`13
`
`
`
`
`
`
`cholesterol OR phospholipid or ((cation* OR ioniz*) W/2
`to accused product
`lipid) OR LNP* OR(lipid W/1 nanoparticle*)) AND (ratio* OR
`considering there are 10+
`(lipid W/2 molar) OR(lipid W/2 content) OR(lipid W/2
`other searchstrings broadly
`
`
`concentration) OR(lipid W/2 conc) OR "##mol\u0025")
`covering SM-102.
`
`
`
`
`
`
`Elasomeran*) AND(ratio* OR(lipid W/2 molar) OR(lipid
`connectors; manyalternate
`
`
`W/2 content) OR(lipid w/2 concentration) OR
`termsthat aren’t synonyms,
`“$##mol\u0025" OR patent* OR(intellectual W/1 propert*)
`far exceeding 10 allowable
`ORIP ORlicens* OR agreement ORsublicens* ORinfring*
`terms.
`OR entrap* OR encapsulat* OR sub-licens* OR target* OR
`mg/mLORInex OR Protiva OR Genevant OR Tekmira OR
`Arbutus OR Acuitas OR AlCana OR Alnylam)
`
`
`previously explained;
`overbroad as it is not limited
`to accused product.
`
`(Emergency Use Authorization OR EUA OR ((BLA OR 28-Feb-2016|28-Feb-2022 63,759 Overbroad; termslike
`
`28-Feb-2012|28-Feb-2022(SM-102 OR SM102 OR SM-000102 OR PEG* OR DSPC OR 7,944 Overbroad; should be limited
`
`(mRNA-1273* OR (mRNA W/1 1273*) OR Spikevax* OR 28-Feb-2016|28-Feb-2022 129,877 ‘Overbroad; no proximity
`
`
`
`
`
`
`
`
`
`28-Feb-2016|28-Feb-2022 170,718 Not relevant for reasons
`
`
`
`(mRNA* OR messenger RNA) W/5 (encapsulat* OR
`deliver*)
`
`1-Jan-2011
`
`28-Feb-2022
`
`99,576
`
`Overbroad;not limited to
`accused product; none ofthe
`asserted claims recite
`delivery.
`10
`
`
`
`28-Feb-2012|28-Feb-2022 9,451 Overbroad, especially
`
`
`
`
`

`

`Case 1:22-cv-00252-MSG Document 134-3 Filed 10/03/23 Page 4 of 4 PageID #: 1843
`Case 1:22-cv-00252-MSG Document 134-3 Filed 10/03/23 Page 4 of 4 PagelD #: 1843
`
`
`
`considering tangential subject
`matter; not sufficiently
`targeted to seek relevant ESI;
`notlimited to accused
`product.
`
`1-07 28-Feb-2012|28-Feb-2022|10 Overbroad;not sufficiently
`limited to accused product or
`a reasonable time period
`considering Plaintiffs justified
`this term as being relevant to
`infringement/1498.
`
` (Mark W/2 Murray) OR (lan W/2 MacLachlan) OR
`
`
`
`
`
`SNALP* ORstable nucleic acid-lipid particle OR stable 28-Feb-2022|101-Jan-2011
`
`nucleic acid-lipid particles OR SPLP* OR stable plasmid lipid
`particle OR stable plasmid lipid particles
`1-Jan-2011 28-Feb-2022|10 Overbroad; targets
`
`
`Fougerolles OR tony@modernatx.cominformation concerning a non-
`inventor (TF) that Plaintiffs
`haven’t alleged had any
`connection to the patents-in-
`suit, and not relevant to any
`claims or defenses. Other
`individuals not sufficiently
`limited to target ES!
`considering aspects of
`asserted claims; exceeds
`number ofESI terms Plaintiffs
`are entitled to. Note Moderna
`did not run new terms that
`Plaintiffs belatedly added
`whenPlaintiffs should have
`been narrowing, not
`broadening.
`
`(mRNA-1273* OR (mRNA W/1 1273*) OR Spikevax* OR 28-Feb-2016|28-Feb-2022|10 Overbroad;not limited to
`
`Elasomeran* ORlipid or LNP
`accused product or even to
`specific assays.
`
`Alina Afinogenova
`KIRKLAND & ELLIS LLP
`200 Clarendon Street, Boston, MA 02116
`T +1 617 385 7526 M +1 917 324 5004
`F +1 212 446 4900
`
`Jina
`
`afi
`
`@hickland
`
`From: Sheh, Anthony <ASheh@wc.com>
`Sent: Friday, September 15, 2023 4:49 PM
`To: Afinogenova,Alina <alina.afinogenova@kirkland.com>; shaelyndawson@mofo.com; *jshaw@shawkeller.com <jshaw@shawkeller.com>; Karen Keller
`<kkeller@shawkeller.com>; Nate Hoeschen <nhoeschen@shawkeller.com>; Genevant Team <GenevantTeam @wc.com>; Arbutus_MoFo <Arbutus_MoFo@mofo.com>
`Cc: Carson, Patricia A. <patricia.carson@kirkland.com>; Wacker, Jeanna <jeanna.wacker@kirkland.com>; McLennan, Mark C. <mark.mclennan@kirkland.com>; Blumenfeld, Jack
`<JBlumenfeld@morrisnichols.com>; Egan, Brian P. <began@morrisnichols.com>; Murray, Travis <tmurray@morrisnichols.com>; #KEModernaSpikevaxService
`<KEModernaSpikevaxService@kirkland.com>
`Subject: RE: Arbutus v. Moderna, 1-22-cv 00252 - Moderna’s Search Terms
`
`This message is from an EXTERNAL SENDER
`Be cautious, particularly with links and attachments.
`
`Alina,
`
`Please see the attached correspondence. Thank you.
`
`Best,
`Tony
`
`Anthony Sheh| Associate | Williams & Connolly LLP | (202) 434-5436 | vcard
`
`From:Afinogenova,Alina <alina.afinogenova@kirkland.com>
`Sent: Tuesday, August 22, 2023 10:10 PM
`To: Sheh, Anthony <ASheh@wccom>; shaelyndawson@mofo.com; *jshaw@shawkellercom<jshaw@shawkellercom>; KarenKeller <kkeller@shawkellercom>; Nate Hoeschen
`<nhoeschen@shawkellercom>; Genevant Team <GenevantTeam@wce.com>; Arbutus_MoFo <Arbutus_MoFo@mofo.com>
`
`